Stock Markets February 5, 2026

Sligro to Unveil Multi-Year Margin Plan After Mixed 2025 Results

Company posts strong cash generation and shareholder returns but struggles to restore pre-pandemic operating margins

By Ajmal Hussain
Sligro to Unveil Multi-Year Margin Plan After Mixed 2025 Results

Sligro Food Group will present a new strategic plan on March 5 that targets structural margin gains across 2026-30 after a 2025 operating performance that fell short of expectations. Adjusted EBIT of
c54 million missed forecasts by 8% as weak sales growth and rising costs limited margin recovery, even as free cash flow reached
c80 million and management announced a
c26 million buyback alongside a
c0.50 dividend per share.

Key Points

  • Sligro missed 2025 adjusted EBIT expectations with c54 million reported, 8% below forecasts, and achieved only a 30 basis point margin improvement.
  • Strong free cash flow of c80 million and low leverage supported a c26 million share buyback and a dividend increase to c0.50 per share.
  • A new strategic plan targeting structural margin gains across 2026-30 will be presented at Capital Markets Day on March 5.

Investors will get a clearer picture of Sligro Food Group's strategy at the company's Capital Markets Day on March 5, where management plans to outline a new multi-year programme focused on structural margin improvement for the 2026-30 period. The move comes after the group struggled to restore operating profitability to pre-COVID levels despite a range of operational initiatives in both the Netherlands and Belgium.

For the year 2025, Sligro reported adjusted EBIT of c54 million, a figure 8% below consensus expectations. Management said sales growth was minimal and that rising operating costs offset cost-reduction measures, producing only a 30 basis point gain in operating margin despite numerous efficiency efforts.

On the cash side, Sligro delivered an exceptionally strong free cash flow performance in 2025, generating c80 million. That cash generation, combined with relatively low debt levels, enabled the board to approve an unanticipated share buyback of c26 million. The company also raised its dividend to c0.50 per share, an outcome that matched market expectations.


Management's outlook for 2026 is cautious. The company expects only limited top-line growth next year and anticipates a modest improvement in operating margin. Against that backdrop, the strategic plan set to be presented on March 5 will concentrate on measures intended to structurally lift margins across the 2026-30 timeframe.

Market analysts have already signalled a guarded stance on the stock. Kepler Cheuvreux retains a Hold rating on Sligro shares and assigns a target price of c10.50. That target implies a downside of 10.4% from the then-current share price of c11.72.

The company faces the dual task of accelerating margin recovery while maintaining the cash returns that underpinned the recent buyback and dividend increase. Management has chosen to prioritise a plan covering a multi-year horizon rather than promising rapid near-term margin rebounds.

Investors will likely focus on the details the group provides on March 5 - specifically which structural levers Sligro intends to deploy across its Dutch and Belgian operations, and how those initiatives will translate into measurable margin progress over 2026-30.

Risks

  • Limited sales growth and rising operating costs could continue to constrain margin recovery in 2026 - affecting profitability in foodservice and wholesale sectors.
  • If structural initiatives fail to produce the expected margin gains during 2026-30, shareholder returns and valuation could be pressured - impacting investor sentiment in consumer-facing retail stocks.

More from Stock Markets

Mixed Earnings Drive Narrow Premarket Moves; Big Tech and Chips Under Pressure Feb 5, 2026 ICE posts higher quarterly profit as trading volumes climb in volatile markets Feb 5, 2026 Captain Sentenced to Six Years After Fatal Collision Between Container Ship and Anchored Tanker Feb 5, 2026 Citi cuts Babcock rating to neutral, cites limited upside after recent rally Feb 5, 2026 Bristol Myers Sees Strong 2026; Eliquis Price Cut Positioned as Growth Engine Feb 5, 2026